CancerVax Corporation Announces Corporate Restructuring
04 Octobre 2005 - 3:07AM
Business Wire
CancerVax Corporation (NASDAQ:CNVX) announced a corporate
restructuring plan today, realigning its resources in light of its
decision to discontinue the Phase 3 clinical trial of Canvaxin(TM)
in patients with Stage III melanoma. The immediate impact of this
restructuring will reduce CancerVax's workforce from 183 to
approximately 80 employees. "This restructuring will allow us to
focus our resources on the development of the other product
candidates in our pipeline and, potentially, to explore the
acquisition of additional promising products and technologies,"
said David F. Hale, President and CEO of CancerVax Corporation. "We
will continue to review our resource requirements as we refine our
strategies over the coming weeks." The decision to discontinue the
Phase 3 clinical trial of Canvaxin(TM) in patients with Stage III
melanoma was based upon the recommendation of the independent Data
and Safety Monitoring Board (DSMB). There were no significant
safety issues identified with either the Phase 3 clinical trial of
Canvaxin(TM) in patients with Stage III melanoma, or with the Phase
3 clinical trial of Canvaxin(TM) in patients with Stage IV
melanoma, which was discontinued earlier this year. The
recommendations to close both of these clinical trials were not
made because of any potential safety concerns. About CancerVax
Corporation (www.cancervax.com) CancerVax Corporation is a
biotechnology company focused on the research, development and
commercialization of novel biological products for the treatment
and control of cancer. CancerVax has been evaluating Canvaxin(TM)
in a Phase 3 clinical trial for the treatment of patients with
Stage III melanoma in collaboration with Serono. CancerVax also has
a pipeline of product candidates and technologies that are being
developed for the potential treatment of cancer. These include
SAI-EGF, a product candidate that targets the epidermal growth
factor (EGF) receptor signaling pathway; and D93, CancerVax's lead
anti-angiogenic humanized monoclonal antibody. CancerVax plans to
file an Investigational New Drug (IND) application for clinical
trials of D93 in early 2006, and to initiate a clinical trial with
SAI-EGF in patients with advanced non-small-cell lung cancer in
2006. Forward Looking Statements CancerVax Corporation CancerVax
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements. For example, statements about the timing of the
initiation of clinical trials with any of CancerVax's product
candidates, and plans and objectives of management, are all
forward-looking statements. The inclusion of forward-looking
statements should not be regarded as a representation by CancerVax
that any of its plans will be achieved. Actual results may differ
materially from those set forth in this release due to the risks
and uncertainties inherent in CancerVax's business including,
without limitation: the progress, timing and outcome of its
clinical trials; its ability to obtain additional financing to
support its operations, which could adversely affect its ability to
continue to operate as a going concern; the risk that the
collaboration agreement for Canvaxin(TM) may be terminated by
Serono in certain instances; the risk that CancerVax may be
required to pre-pay the debt incurred to expand its manufacturing
capacity prior to the termination of the loan because of a failure
to comply with covenants included in the loan agreement; unexpected
adverse side effects or inadequate therapeutic efficacy of its
product candidates that could delay or prevent product development
or commercialization, or that could result in recalls or product
liability claims; competition from other pharmaceutical or
biotechnology companies; CancerVax's limited experience in
manufacturing and testing biological products, which may result in
delayed development or commercialization of its product candidates,
as well as lost revenue; and other risks detailed in CancerVax's
Securities and Exchange Commission filings, including CancerVax's
Annual Report on Form 10-K for the fiscal year ended December 31,
2004, and Quarterly Report for the fiscal quarter ended June 30,
2005. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement and CancerVax undertakes no obligation to
revise or update this news release to reflect events or
circumstances after the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. CancerVax(R) is a registered trademark of CancerVax
Corporation. Canvaxin(TM) is a trademark of CancerVax Corporation.
Cancervax (NASDAQ:CNVX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cancervax (NASDAQ:CNVX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Cancervax (MM) (NASDAQ): 0 recent articles
Plus d'articles sur CancerVax Corporation